Q3 net profit rises 54%; Rs 75 interim dividend declared
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q3 FY26 revenue rose 3.4% to Rs 4,917 million and net profit rose 54% to Rs 1,167 million. Profit before tax and one-off items rose 22% to Rs 1,577 million; margin improved to 34% from 29%. Diabetes sales grew 9%. Nine-month revenue slipped 1.1% to Rs 14,017 million, while net profit rose 14% to Rs 3,028 million. Last year's quarter included Rs 273 million of separation costs. The board declared an interim dividend of Rs 75 per share.
Strong Q3 profit growth and the dividend may support sentiment, though nine-month revenue decline and a one-off provision reversal warrant caution.